Tclin FLT3 Receptor-type tyrosine-protein kinase FLT3

Protein Summary

Description

Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways. This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015]

Uniprot Accession IDs

• P36888
• A0AVG9
• B7ZLT7
• B7ZLT8
• F5H0A0
• Q13414

Gene Name

• FLT3

Ensembl ID

• ENST00000241453
• ENSP00000241453
• ENSG00000122025

Symbol

• CD135
• FLK2
• STK1
• FLK2
• STK1
• CD135
• FLK-2

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
molecular function	1
protein domain	1
biological process	0.98
small molecule	0.95
biological term	0.93

Protein Classes

DTO Classes

Protein / Kinase / Protein Kinase / Tk Group / Pdgfr Family / Receptor-type Tyrosine-protein Kinase Flt3

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 3617.75   (req: < 5)

Gene RIFs: 696   (req: <= 3)

Antibodies: 1452   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 3617.75   (req: >= 5)

Gene RIFs: 696   (req: > 3)

Antibodies: 1452   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 40

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 1033

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 13